Next-Generation Sequencing (NGS)
Company
Analysis
Asia & Europe
Created for
------
Table of Content
An Overview
SWOT
Competitor Analysis
- GENEWIZ
- Oxford Nanopore Technologies
- Macrogen
- BGI Genomics
- QIAGEN
- Hoffmann-La Roche
- Eurofins Scientific
- Genotypic Technology
- DNA Link
- Dante Labs
- Sophia Genetics
- Novogene
- Centogene
- Devyser
An Overview
A rapid growth is witnessed in clinical NGS - the global clinical NGS services market was $2.2 billion in 2015 and is
forecast to reach $7.7 billion by 2020. The reproductive health NGS test market is the largest market followed by the
oncology NGS test market. The largest market is for tests that sequence >50 genes but not the entire exome or
genome. Markets are growing rapidly in countries outside of the US. Despite rapid NGS test growth, there are a
number of key issues that will need to be addressed to facilitate appropriate future growth.
As far as the market size for NGS products is concerned, it is growing. This market was nearly $5.9 billion in 2015 and
is forecast to reach $13.8 billion by 2020 (18.7% CAGR). A substantial and growing component of this market is
represented by NGS services provided by companies that provide either raw data or a report to users. The total NGS
services market was nearly $2.9 billion in 2015 and is forecast to reach $9.1 billion by 2020 (26.0% CAGR). One key
trend is the transition from the use of Sanger-based sequencing to NGS sequencing, with an expected decrease in
the market for Sanger-based instruments and consumables of almost 5% CAGR by 2020.
Worldwide Market Size of Clinical NGS by Application
NGS tests are used for a variety of clinical applications worldwide. The reproductive health NGS test market is the
largest market (54%) at $1.7 billion in 2017, and is expected to reach $3.3 billion by 2022 (13.8% CAGR).This consists
of NIPT (the largest category), carrier screening, in vitro fertilization, and newborn screening.
The oncology NGS test market makes up the second largest market (27%) at $838.8 million in 2017, and is forecast to
reach $4.1 billion by 2022 (37.3% CAGR).
Other applications include Mendelian (rare) disorders, complex diseases, and transplant diagnostics.
Clinical applications can be further segmented by whether they are considered “current” or “emerging” markets.
Current markets include cancer, HLA typing (for transplants), Mendelian disorders, metabolic and immune disorders,
prenatal testing, and IVF. Emerging markets include cardiovascular, food-borne illness, neurological, and newborn
screening.
Worldwide Market Size of Clinical NGS by Type of Test
The global clinical NGS market can also be segmented by the type of test. The largest market is for tests that
sequence >50 genes but not the entire exome or genome. This market is estimated to be almost $2.6 billion in 2017
and forecast to reach $5.2 billion in 2022 (15.3% CAGR).
However, the markets for whole exome and genome sequencing tests are rapidly increasing from their small base.
The exome sequencing market is estimated at $152.2 million in 2017 and is forecast to reach a size of $1.3 billion in
2022 (53.9% CAGR), while the whole genome sequencing market is estimated at $32.9 million in 2017 but expected
to reach $1.0 billion in 2022 (98.8% CAGR).
SWOT
Strength Weakness
• The major strength of next-generation • NGS requires sophisticated bioinformatics
sequencing is that the method can detect systems, fast data processing and large data
abnormalities across the entire genome, storage capabilities which adds on the
including substitutions, deletions, insertions, infrastructure costs associated with the same.
duplications, copy number changes, and
chromosome inversions/translocations. • One of the other weaknesses/limitations of
NGS is that it provides information on a number
• NGS is capable of detecting all the above- of molecular aberrations but for many of the
mentioned abnormalities using less DNA than identified abnormalities, the clinical significance
required for traditional DNA sequencing is currently unknown. This greatly hampers the
approaches. trenchant application of NGS to a wider arena.
• Additionally, some other key strengths of NGS • Some of the NGS platforms like '454 Platform'
include its low cost, high accuracy, impeccable can involve time-consuming sample
speed, and precise results even from low preparation protocols which include emPCR.
sample input as compared to other traditional
methods such as Sanger's sequencing method.
• The NGS has the potential to accelerate the
early detection of disorders and the
identification of pharmacogenetics markers to
customize its treatments.
Opportunity Threat
• The development and growth of the • One of the major threats/risks associated with
personalized medicine sector have opened NGS pertains to the difficulty in the
many avenues for the usage of NGS which has a management of large data and complications,
huge number of applications in personalized associated with Big Data management. NGS
medicine field. The various technological uses a colossal amount of data and wrong or
advancements in the field of personalized inefficient data handling can be a great threat
medicine act as a key opportunity for NGS. to the efficacy of NGS.
• Another key opportunity area for NGS is genetic • In addendum, the NGS market faces the
screening, where the same is extremely threat/risk of some ethical issues associated
trenchant in identifying "monogenic diseases with whole-genome sequencing along with the
with locus heterogeneity, such as blindness, lack of awareness among people.
deafness, movement disorders, mitochondrial
disease, hereditary cancers". • The costs involved in 'Library preparation' for
human whole-genome sequencing at $50
• Infectious disease diagnostics is the next sample can be a risk in its application in areas
opportunity area where NGS can emerge as a such as sequencing bacterial genomes or low-
more powerful and promising pathogen- depth RNA sequencing (RNA-seq) where this
detection method. It helps in the identification constitutes majority of the cost.
and genomic characterization of bacteria, fungi,
parasites, and viruses, without the need for
prior knowledge of a specific pathogen, directly
from clinical specimens.
• The utilization of cloud computing in NGS for
data management and untapped emerging
economies are expected to provide new market
opportunities to NGS manufacturers in the near
future.
Company Analysis
GENEWIZ
https://www.genewiz.com/
Phone
49 (0)341 520 122-41
Email
[email protected]
Kerstin Stangier, Senior Director, GENEWIZ Europe
Jason W. Joseph, Managing Director
[email protected]David F. Pietrantoni, Managing Director
Amy Liao, President
[email protected] About
GENEWIZ, a Brooks Life Sciences Company, is a leading Founded
global genomics service provider serving thousands of 1999
researchers in institutions worldwide. GENEWIZ offers a
suite of solutions including DNA synthesis, sanger HQ Location
sequencing and next generation sequencing to Leipzig, Germany and South Plainfield, NJ
accelerate antibody discovery and development
research. Other services also include bioinformatics, Revenue
GLP regulatory, and clinical services. $126.3mn
GENEWIZ has more than 4,000 customers globally,
which includes many of our over 1,500 sample Specialties
management customers. Sanger Sequencing, Gene Synthesis, Next Generation
Sequencing, DNA Sequencing, Mutation Analysis, SNP
Discovery, Sequencing from Bacteria and Phage,
Difficult Template Sequencing, Plasmid Preparation,
Site-directed Mutagenesis, Fragment Analysis,
Molecular Genomics, and Regulatory
Parent Company
Brooks Automation, Inc.
Accreditation
GENEWIZ Regulatory Services, located in South GENEWIZ Suzhou, China and Takeley, UK locations also
Plainfield, NJ, are subject to rigorous quality systems hold the ISO:9001 Quality Management Certification, a
based on Good Laboratory Practice (GLP), Clinical voluntary international certification noting operational
Laboratory Improvement Amendments (CLIA) excellence and quality standards.
regulations and College of American Pathologist (CAP)
standards.
Services
Amplicon Sequencing Clinical Sequencing
- Amplicon-EZ for 150-500 bp - CLIA Whole Genome
- Custom Short-Read - CLIA Whole Exome
- Long-Read up to 20 kb - RUO Assays in CLIA Environment
RNA Sequencing Epigenomics
- Standard and Strand-Specific for mRNA and - Whole Genome Bisulfite Seq
lncRNA - Methylome Seq on PacBio®
- Small RNA - ATAC-Seq
- Ultra-Low Input - ChIP-Seq
- Single-Cell Analysis
- Isoform Sequencing Immunogenomics
- Bulk and Single-Cell Immune
Whole Genome Sequencing - Repertoire Profiling
- Short- and Long-Read
- Haplotype Phasing on 10x Genomics Metagenomics
- Whole Genome Metagenomics
Targeted Sequencing - 16S Assay for Bacterial ID
- Whole Exome - ITS2 Assay for Fungal ID
- Cancer & Custom Gene Panels
- CRISPR Validation Assay
SWOT
Strength Weakness
- Company’s technology. No such weakness found
- Patent rights and other intellectual property
rights to maintain our competitive position.
- Expansion of market reach by investing in
internal product development.
- Strengthened and broadened our product
portfolio.
- Accelerating the growth with further
acquisitions.
Oxford Nanopore Technologies
https://nanoporetech.com/
Phone
44 (0)845 034 7900
Email
[email protected]
Hagan Bayley, Founder
Clive G. Brown, CTO
[email protected]Gordon Sanghera, CEO
[email protected] About
Oxford Nanopore Technologies Limited is a UK-based Founded
company which is developing and selling nanopore 2005
sequencing products (including the portable DNA
sequencer, MinION) for the direct, electronic analysis of HQ Location
single molecules. Oxford, UK
Oxford Nanopore has developed the worlds first and
only nanopore DNA sequencer, the MinION. Nanopore Revenue
sensing technology is fully scalable. The GridION X5 is a $62.3mn (2019)
desktop device that includes compute module and the $43.7mn (2018)
ability to run up to five MinION Flow Cells. $17.8mn (2017)
Specialties
DNA sequencing and Next Generation Sequencing
Funding
£613 million
- Seed funding was obtained in two rounds, from - In October 2013 Oxford Nanopore raised £40m
IP Group in 2005. from new and existing investors in the US and
- In June 2006 the company raised £7.75m Europe.
- In March 2008 the company raised a further - In August 2014 Oxford Nanopore raised £35m
£10m. from new and existing investors in the US and
- In January 2009 the Company announced an Europe.
$18m (£11.9m) and a separate £2.1m - In July 2015 Oxford Nanopore raised £70m
investment from new and existing investors in the US and
- In February 2010 Oxford Nanopore raised Europe.
£17.4m from existing investors and new, - In December 2016 Oxford Nanopore raised
undisclosed US-based investors. £100m from new and existing investors
- In April 2011 the Company raised £25m from worldwide.
existing and new institutional and independent - In March 2018 Oxford Nanopore raised £100M
investors based in the UK and US. ($140M) from global investors
- In May 2012 the Company raised £31.4m - In 2020 Oxford Nanopore announced that it
($50.8m), the majority of which was from had raised £29M + £49.4M +£84.4M in new
existing investors. capital in three tranches
Accreditation
- Kinghorn Centre for Clinical Genomics (KCCG) - ISO 27001
- ISO 9001
Products
- RESEARCH PRODUCTS - Q-LINE
Real-time DNA and RNA sequencing — from Locked-down, research-validated devices for
portable to high-throughput devices. applied sequencing applications.
- COVID-19
Integrated workflows for real-time detection
and monitoring of SARS-CoV-2.
Applications
Research areas Investigations
- Microbiology - Structural variation
- Microbiome - SNVs and phasing
- Environmental - Gene expression
- Plant - Identification
- Animal - Splice variation
- Human genomics - Assembly
- Clinical research - Fusion transcripts
- Cancer - Chromatin conformation
- Transcriptome - Epigenetics
- Populations genomics - Single cell
Techniques
- Whole genome
- Targeted
- Whole transcriptome
- Metagenomics
SWOT
Strength Weakness
- The release of the MinION platform in 2014 - Although ONT is already established at the
established ONT at the forefront of low-cost forefront of third-generation sequencing,
third-generation sequencing platforms. several limitations of the technology remain,
especially for sequencing highly repetitive plant
- Creation and development of sample and genomes.
library preparation protocols for a wide variety
of sample types, and undertaking biological
projects.
